Genomic changes as causes for malignant diseases were intensively studied in the past and their profiling is efficiently integrated in the clinical routine. Genetic alterations lead to changes in essential cellular processes, such as cell survival and metabolism, whose activation status can be read out in the proteome and phosphoproteome.
Thus, the integration of genomic, proteomic and phosphoproteomic data of cancer patients gains more and more importance for detailed diagnostics and the identification of new therapeutic targets, due to a better accessibility of proteins as target structures. This is why, several MSTARS partners focus on a mass spectrometry (MS)-based deep analysis of proteomic alterations and join forces to implement standardized and advanced proteomic analyses that may be applied in the clinics in the future. An immediate goal is also to identify proteomic signatures that support therapy recommendations.